易普利姆玛
医学
CTLA-4号机组
免疫疗法
银耳霉素
免疫系统
免疫检查点
免疫学
癌症
细胞毒性T细胞
癌症研究
乳腺癌
癌症免疫疗法
T细胞
肿瘤科
内科学
生物
生物化学
体外
作者
S. G. Dehbokri,Nazila Alizadeh,Alireza Isazadeh,Amir Baghbanzadeh,Soheil Abbaspour-Ravasjani,Khalil Hajiasgharzadeh,Behzad Baradaran
出处
期刊:Current Molecular Medicine
[Bentham Science]
日期:2022-06-10
卷期号:22
被引量:1
标识
DOI:10.2174/1566524022666220610094716
摘要
Breast cancer (BC) is one of the prevalent diseases and causes of death in women, and its incidence rate is increasing in numerous developed and developing countries. The common approach to BC therapy is surgery, followed by radiation therapy or chemotherapy that doesn't lead to acceptable outcomes in many patients. Therefore, developing innovative strategies for the treatment of BC is an essential need for the most effective therapy. The immunotherapy of the BC is a promising and attractive strategy, which can increase the capacity of the immune system to recognize and kill the tumor cells and inhibit the recurrence of the tumors as well as the development of new metastatic sites. The blockade of immune checkpoints is the most attractive and promising strategy for cancer immunotherapy. The cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a cell-surface glycoprotein expressed by stimulated T cells and has pivotal roles in cell cycle modulation, cytokine generation, and regulation of the T cells proliferation. Currently, anti-CTLA-4 agents such as monoclonal antibodies (Ipilimumab and tremelimumab) are broadly applied as therapeutic agents in clinical studies of different cancers. The anti-CTLA-4 antibodies, alone or combined with other therapeutic agents, remarkably increased the tumor-suppressive effects of the immune system and improved the prognosis of cancer. The immune checkpoint inhibitors may represent promising options for BC treatment as in monotherapy or in combination with other conventional treatments. In this review, we discuss the role of CTLA-4 and its therapeutic potential by inhibitors of immune checkpoints in BC therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI